|
|
Contents
|
|
|
BCR
AFTER PRIMARY RADICAL PROSTATECTOMY
■
SALVAGE
RADIATION THERAPY (SRT) AFTER RP
■
SURVIVAL
FOLLOWING SRT
■
TEMPORAL
ASSOCIATION TO BONE METASTASIS
BCR
AFTER PRIMARY RADIATION THERAPY
|
|
|
BCR
AFTER PRIMARY RADICAL PROSTATECTOMY
|
|
.*
|
Amling
CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke
H.
Long-term
hazard of progression after radical prostatectomy for clinically
localized prostate cancer: continued risk of biochemical failure
after 5 years.
J
Urol. 2000 Jul;164(1):101-5.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Antonarakis
ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh
PC, Eisenberger MA.
The
natural history of metastatic progression in men with
prostate-specific antigen recurrence after radical prostatectomy:
long-term follow-up.
BJU
Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x.
Epub 2011 Jul 20.-710
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Bessede
T, Patard JJ.
Re:
The Use of Early Postoperative Prostate-specific Antigen to
Stratify Risk in Patients with Positive Surgical Margins After
Radical Prostatectomy.
Eur
Urol. 2016 Feb;69(2):372. doi:
10.1016/j.eururo.2015.10.061.*
Source
|
Full
text |
Similar
articles
|
|
|
.*
|
Boorjian
SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML,
Karnes RJ.
Long-term
risk of clinical progression after biochemical recurrence
following radical prostatectomy: the impact of time from surgery
to recurrence.
Eur
Urol. 2011 Jun;59(6):893-9. doi: 10.1016/j.eururo.2011.02.026.
Epub 2011 Feb 22.-709
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Brockman
JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW,
Bianco FJ Jr, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW,
Stephenson AJ.
Nomogram
Predicting Prostate Cancer-specific Mortality for Men with
Biochemical Recurrence After Radical Prostatectomy.
Eur
Urol. 2015 Jun;67(6):1160-7. doi: 10.1016/j.eururo.2014.09.019.
Epub 2014 Oct 6.-711
Source
|
Full
text |
Similar
articles
|
|
|
.
|
D'Amico
AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.
Prostate
specific antigen doubling time as a surrogate end point for
prostate cancer specific mortality following radical prostatectomy
or radiation therapy.
J
Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.-712
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Freedland
SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC,
Partin AW.
Risk
of prostate cancer-specific mortality following biochemical
recurrence after radical prostatectomy.
JAMA.
2005 Jul 27;294(4):433-9.-713
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Guillonneau
BD, Fizazi K.
Natural
history of patients presenting biochemical recurrence after
radical prostatectomy: some good news?
Eur
Urol. 2011 Jun;59(6):900-1. doi: 10.1016/j.eururo.2011.02.043.
Epub 2011 Mar 17.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Karl
A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer
R, Burger M, Eder F, Hofstädter F, Schilling D, Sievert K,
Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Schmid K,
Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke
R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A,
Hanspeter E, Pehrke D, Sauter G, Graefen M, Stief C, Haese A.
The
natural course of pT2 prostate cancer with positive surgical
margin: predicting biochemical recurrence.
World
J Urol. 2015 Jul;33(7):973-9. doi: 10.1007/s00345-015-1510-y. Epub
2015 Feb 15.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Mauermann
J, Fradet V, Fradet Y.
Reply
from authors re: Martin Spahn, Steven Joniau. Positive surgical
margin at radical prostatectomy: futile or surgeon-dependent
predictor of prostate cancer death? Eur Urol 2013;64:26-8:
adjuvant versus salvage radiotherapy in patients with positive
surgical margins at radical prostatectomy: that is the
question.
Eur
Urol. 2013 Jul;64(1):28-9. doi: 10.1016/j.eururo.2012.10.047. Epub
2012 Nov 5.
Source
|
Full
text |
Similar
articles
|
|
|
.*
|
Mauermann
J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet
Y.
The
impact of solitary and multiple positive surgical margins on hard
clinical end points in 1712 adjuvant treatment-naive pT2-4 N0
radical prostatectomy patients.
Eur
Urol. 2013 Jul;64(1):19-25. doi: 10.1016/j.eururo.2012.08.002.
Epub 2012 Aug 10.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Mithal
P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ,
Amling C, Freedland SJ.
Positive
surgical margins in radical prostatectomy patients do not predict
long-term oncological outcomes: results from the Shared Equal
Access Regional Cancer Hospital (SEARCH) cohort.
BJU
Int. 2016 Feb;117(2):244-8. doi: 10.1111/bju.13181. Epub 2015 Jun
23.*
Source
|
Full
text |
Similar
articles
|
|
|
.**
|
Pound
CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh
PC.
Natural
history of progression after PSA elevation following radical
prostatectomy.
JAMA.
1999 May 5;281(17):1591-7.-363
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Scher HI.
Management of prostate cancer after
prostatectomy: treating the patient, not the PSA.
JAMA.
1999 May 5;281(17):1642-5.
Comment
on: Pound
CR et al, Natural history of progression after PSA elevation
following radical prostatectomy. [JAMA. 1999]
Source
| Full
text |
Similar
articles
|
|
|
.*
|
Spahn
M, Joniau S.
Positive
surgical margin at radical prostatectomy: futile or
surgeon-dependent predictor of prostate cancer death?
Eur
Urol. 2013 Jul;64(1):26-8. doi: 10.1016/j.eururo.2012.08.063. Epub
2012 Sep 5.*
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Ün
S, Türk H, Koca O, Divrik RT, Zorlu F.
Factors
determining biochemical recurrence in low-risk prostate cancer
patients who underwent radical prostatectomy.
Turk
J Urol. 2015 Jun;41(2):61-6. doi: 10.5152/tud.2015.65624.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Vesely
S, Jarolim L, Duskova K, Schmidt M, Dusek P, Babjuk M.
The
use of early postoperative prostate-specific antigen to stratify
risk in patients with positive surgical margins after radical
prostatectomy.
BMC
Urol. 2014 Oct 2;14:79. doi: 10.1186/1471-2490-14-79.*
Source
|
Full
text |
Similar
articles
|
|
|
.*
|
Ward
JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H.
The
long-term clinical impact of biochemical recurrence of prostate
cancer 5 or more years after radical prostatectomy.
J
Urol. 2003 Nov;170(5):1872-6.
Source
|
Full
text |
Similar
articles
|
|
|
SALVAGE
RADIATION THERAPY (SRT) AFTER RP
|
|
|
|
BCR
AFTER SRT
|
|
.
|
Briganti
A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G,
Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M,
Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.
Prediction
of outcome following early salvage radiotherapy among patients
with biochemical recurrence after radical prostatectomy.
Eur
Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045.
Epub 2013 Dec 12.-714
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Williams
SB, Hu JC.
Predicting
biochemical recurrence following salvage radiotherapy: applying
lessons learned from primary radiotherapy.
Eur
Urol. 2014 Sep;66(3):487-8. doi: 10.1016/j.eururo.2013.12.048.
Epub 2014 Jan 2.
Source
|
Full
text |
Similar
articles
|
|
|
SURVIVAL
FOLLOWING SRT
|
|
.
|
Eastham
JA.
Words
of wisdom. Re: Prostate cancer-specific survival following salvage
radiotherapy versus observation in men with biochemical recurrence
after radical prostatectomy. Trock BJ, Han M, Freedland SJ,
Humphreys EB, DeWeese TL, Partin AW, Walsh PC. JAMA
2008;299:2760-9.
Eur
Urol. 2009 Jan;55(1):247.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Parker
C, Sydes M.
Adjuvant
radiotherapy after surgery for prostate cancer.
JAMA.
2008 Nov 12;300(18):2119; author reply 2119. doi:
10.1001/jama.2008.562.
Comment
on: Trock BJ et al, Prostate cancer-specific survival following
salvage radiotherapy vs observation in men with biochemical
recurrence after radical prostatectomy. [JAMA. 2008 Jun 18]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Trock
BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW,
Walsh PC.
Prostate
cancer-specific survival following salvage radiotherapy vs
observation in men with biochemical recurrence after radical
prostatectomy.
JAMA.
2008 Jun 18;299(23):2760-9. doi:
10.1001/jama.299.23.2760.-715
Source
|
Full
text |
Similar
articles
|
|
|
TEMPORAL
ASSOCIATION TO BONE METASTASIS
|
|
|
Mahdy A, Patil R, Parajuli S.
Biochemical Recurrence in
Prostate Cancer and Temporal Association to Bone Metastasis.
Am J Case Rep. 2019 Oct 16;20:1521-1525. doi:
10.12659/AJCR.918569.
Source
.
Similar
articles
|
|
|
BCR
AFTER PRIMARY RADIATION THERAPY
|
|
.
|
D'Amico
AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.
Prostate
specific antigen doubling time as a surrogate end point for
prostate cancer specific mortality following radical prostatectomy
or radiation therapy.
J
Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7.-712
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Denham
JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Matthews
J, Tai KH, Spry NA, Christie D, Gleeson PS, Greer PB, D'Este C;
Trans-Tasman Radiation Oncology Group 96.01 Trialists.
Time
to biochemical failure and prostate-specific antigen doubling time
as surrogates for prostate cancer-specific mortality: evidence
from the TROG 96.01 randomised controlled trial.
Lancet
Oncol. 2008 Nov;9(11):1058-68. doi: 10.1016/S1470-2045(08)70236-5.
Epub 2008 Oct 15.-716
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Freedland
SJ.
PSA
kinetics and surrogacy: ready for prime time?
Lancet
Oncol. 2008 Nov;9(11):1025-6. doi: 10.1016/S1470-2045(08)70267-5.
Comment
on: Denham JW, Time to biochemical failure and prostate-specific
antigen doubling time as surrogates for prostate cancer-specific
mortality: evidence from the TROG 96.01 randomised controlled
trial. [Lancet Oncol. 2008 Nov]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Roach
M 3rd.
Natural
History after Biochemical Failure Following Dose-escalated
External Beam Radiation: An Opportunity to Improve Outcomes?
Eur
Urol. 2015 Jun;67(6):1017-8. doi: 10.1016/j.eururo.2014.10.015.
Epub 2014 Oct 28.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zumsteg
ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride
S, Kollmeier M, Yamada Y, Zelefsky MJ.
The
natural history and predictors of outcome following biochemical
relapse in the dose escalation era for prostate cancer patients
undergoing definitive external beam radiotherapy.
Eur
Urol. 2015 Jun;67(6):1009-16. doi: 10.1016/j.eururo.2014.09.028.
Epub 2014 Oct 11.-717
Source
|
Full
text |
Similar
articles
|
|
|
|
|
|
|
